MDA Families Take to Capitol Hill

A delegation of dozens of MDA advocates from 23 states visited more than 100 congressional offices on Capitol Hill earlier this week to speak to their representatives about the importance of programs and policies that help accelerate the development of treatments and cures for individuals and families living with muscular dystrophy, ALS and related neuromuscular diseases.

Read More

What is Advocacy and Why Should You Care?

health care reform bill

In advance of MDA’s first ever Advocacy Conference, taking place April 23-25, we asked several advocates to unpack the idea of advocacy: what is it, why they became advocates and why it is necessary for others to follow their examples. Their responses follow.

Read More

MDA Cohosts and Sends Representatives to SMA Patient Focused Drug Development Meeting with FDA

PFDD

Being chosen to speak in front of the FDA and represent the SMA community makes me feel incredibly honored. Today’s SMA Patient-Focused Drug Development (PFDD) meeting with the FDA means we have a voice as patients living with rare muscle diseases. The PFDD meeting was set up so that patients with SMA and the parents of children with SMA could stand before the FDA and voice their concerns, discuss their experiences with research and address the need for continued research that evolves to include more patients. This is my story.

Read More

Volunteerism at its best

Here’s how I see it: If families are at the heart of everything MDA does, then volunteers are the lifeblood that energizes our every heartbeat. Bob Bennett and Dr. Chris Rosa exemplify not only the best of our volunteers, but also the best of people.

Read More

MDA Moves Newborn Screening Forward in Partnership with Cure SMA

This September as we recognize Newborn Screening Awareness month, we are proud to announce a new partnership with Cure SMA aimed at moving newborn screening forward for spinal muscular atrophy (SMA)—the leading genetic cause of death in infants. This is an exciting time for the neuromuscular disease community as decades of research are translating into . . .

Read More

Make Sure Your Voice is Heard. Vote!

Voting is a privilege of living in a democratic society, and, for people with disabilities, it is one of the most important ways to promote leaders that best represent your values. But the voice of the disability community is only as loud and as strong as the number of disability advocates that are registered to . . .

Read More

Developments in SMA Highlight Connections Between Advocacy and Research

Every August is Spinal Muscular Atrophy Awareness Month, and this year we have a lot to celebrate. At the beginning of August, Biogen and IONIS Pharmaceuticals announced encouraging results from a late-stage clinical trial testing an experimental drug for infants with SMA type 1. The drug is called nusinersen and is designed to increase production . . .

Read More